Drug class
Fibrate lipid-modifying agent; peroxisome proliferator-activated receptor alpha (PPARα) agonist
Mechanism of action
Activates PPARα, increasing lipoprotein lipase activity and fatty-acid oxidation and reducing hepatic triglyceride-rich lipoprotein production. This lowers triglycerides and can increase HDL cholesterol.
General use cases
- Treatment of dyslipidaemia, particularly hypertriglyceridaemia and mixed dyslipidaemia, in adults when diet and lifestyle measures are inadequate and where bezafibrate is authorised; not a substitute for statin therapy when statins are indicated
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
